ASTRAZEN

AstraZeneca Pharma India Share Price

₹6,415.65 -357.3 (-5.28%)

18 Nov, 2024 20:03

SIP TrendupStart SIP in ASTRAZEN

Start SIP

Performance

  • Low
  • ₹6,359
  • High
  • ₹6,774
  • 52 Week Low
  • ₹4,510
  • 52 Week High
  • ₹8,139
  • Open Price₹6,735
  • Previous Close₹6,773
  • Volume33,447

Investment Returns

  • Over 1 Month -15.89%
  • Over 3 Month -3.34%
  • Over 6 Month + 11.4%
  • Over 1 Year + 37.37%
SIP Lightning

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

Invest Now

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 195.8
  • PEG Ratio
  • -4.2
  • Market Cap Cr
  • 16,039
  • P/B Ratio
  • 22.5
  • Average True Range
  • 315.53
  • EPS
  • 51.49
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -21.12
  • RSI
  • 31.22
  • MFI
  • 60.28

AstraZeneca Pharma India Financials

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹6,415.65
-357.3 (-5.28%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹7,235.28
  • 50 Day
  • ₹7,220.09
  • 100 Day
  • ₹6,960.73
  • 200 Day
  • ₹6,425.48

Resistance and Support

6516.08 Pivot Speed
  • R3 7,087.47
  • R2 6,930.48
  • R1 6,673.07
  • S1 6,258.67
  • S2 6,101.68
  • S3 5,844.27

What's your outlook on AstraZeneca Pharma India?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Ltd. is a global, science-led pharmaceutical company dedicated to transforming healthcare through innovative medicines in oncology, biopharmaceuticals, and rare diseases. it focuses on improving patient outcomes and advancing healthcare worldwide.

Astrazeneca Pharma India has an operating revenue of Rs. 1,484.51 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 17% is great, ROE of 22% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 6% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -10% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 32 which is a POOR score indicating inconsistency in earnings, a RS Rating of 64 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Audited Results & Dividend
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results
Date Purpose Remarks
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend

AstraZeneca Pharma India F&O

AstraZeneca Pharma India Shareholding Pattern

75%
5.05%
0%
2.9%
0%
14.78%
2.27%

About AstraZeneca Pharma India

  • NSE Symbol
  • ASTRAZEN
  • BSE Symbol
  • 506820
  • ISIN
  • INE203A01020

Similar Stocks to AstraZeneca Pharma India

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹6,415 As on 18 November, 2024 | 19:49

The Market Cap of AstraZeneca Pharma India is ₹16039.1 Cr As on 18 November, 2024 | 19:49

The P/E ratio of AstraZeneca Pharma India is 195.8 As on 18 November, 2024 | 19:49

The PB ratio of AstraZeneca Pharma India is 22.5 As on 18 November, 2024 | 19:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23